Market capTH did a consolidation because they had no choice if they want to raise funds and bring back institutional investors. With a residual market cap of only CAD$90 million, the future belongs mostly to new shareholders (and current ones who dare increase their exposure). The company will need to raise 50-60 million if they continue their R&D program (so around 75% dilution). With a potential new market cap of CAD $140 million, it would still be valued TWICE less than when it announced it was pausing the Phase 1 trial.
Think market cap, not stock price when you value the company. So much useless noise right now.